Original article
Lidocaine patch for acute pain management: a meta-analysis of prospective controlled trials

Yaowu Bai
Department of Anesthesiology, Tangshan Maternal and Child Healthcare Hospital, Hebei United University, Tangshan, China

Timothy Miller
Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA

Mingjuan Tan
Duke-NUS Graduate Medical School, Singapore

Lawrence Siu-Chun Law
Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA

Address for correspondence:
Tong Joo Gan MD, Department of Anesthesiology, Stony Brook Medicine, Stony Brook, NY 11794-8480, USA.
tong.gan@stonybrookmedicine.edu

Keywords:
Acute pain – Lidocaine patch – Opioid sparing – Postoperative pain

Abstract

Background:
Local anesthetic is one of the cornerstones of multimodal analgesia. We investigated the efficacy of the lidocaine patch for acute pain management.

Methods:
We searched MEDLINE, CINAHL, Scopus, and the Cochrane Controlled Trials Register for published prospective controlled clinical trials that evaluated the analgesic effect of the lidocaine patch for acute or postoperative pain management (1966–2014). The outcomes were postoperative opioid consumption, pain intensity and length of hospital stay.

Results:
Five trials comparing the lidocaine patch with control (no treatment/placebo) for acute or postoperative pain treatment/management were included in this meta-analysis. Data was analyzed on 251 patients. Between the lidocaine patch group and the control group, no significant difference was found for all three outcomes (all p > 0.05). For postoperative opioid consumption, mean difference (MD) was −8.2 mg morphine equivalent (95% CI −28.68, 12.24). For postoperative pain intensity, MD was −9.1 mm visual analog scale or equivalent (95% CI −23.31, 5.20). For length of hospital stay, MD was −0.2 days (95% CI −0.80, 0.43).

Conclusion:
Application of a lidocaine patch may not be an effective adjunct for acute and postoperative pain management, in terms of pain intensity, opioid consumption and length of hospital stay.

Limitations:
The limitations were a small number of included studies, potential biases from some unblinded studies, clinical heterogeneity between studies, and incomplete reported data for adjunct analgesics.

Introduction

Acute pain is defined as ‘pain of recent onset and probable limited duration’. It has an identifiable causal and temporal relationship to injury, surgery, or disease. Acute pain can lead to patient anxiety, stress and dissatisfaction. Inadequately treated pain may cause organ dysfunction, and can lead to detrimental psychological, economic and social effects. Adequate pain control should be achieved not only for humanitarian reasons, but is also because it is an important goal to allow patients to resume normal activities.

Evidence suggests that multimodal analgesia, where combinations of two or more analgesics with different mechanisms of action are administered, is more effective than monotherapy. Multimodal analgesia techniques provide...
improved analgesia with lower doses than would be possible with a single analgesic, reduce opioid related side effects, and shorten length of hospital stay\textsuperscript{5,6}.

Local anesthetics have been widely used as part of a multimodal technique. There are many routes of administration for lidocaine, such as topical, intravenous, localized subcutaneous or submucosal infiltration, spray, nerve blocks, transdermal patches, etc. Of those routes, intravenous lidocaine has been extensively researched. Two meta-analyses\textsuperscript{7,8} show that intravenous lidocaine significantly reduces postoperatively pain, opioid consumption, length of stay, and gastrointestinal recovery time. The choice of the route of administration is dependent upon several factors, including the site of surgery or injury, intended duration of action, ease of use, expertise required as well as potential adverse effects.

The topical lidocaine 5\% patch is approved by the US Food and Drug Administration for the treatment of persistent neuropathic pain syndrome and postherpetic neuralgia. However, its use has been reported in a number of other painful conditions\textsuperscript{9–11}. The benefits of using a lidocaine patch for the management of acute pain remain unclear. Only a few studies have investigated the efficacy of lidocaine patches on acute pain, and no meta-analysis has been conducted\textsuperscript{2,12}. We therefore conducted this meta-analysis to evaluate the efficacy of lidocaine patches for acute or postoperative pain management. Our hypotheses were that the use of a lidocaine patch reduced pain scores and opioid consumption (primary outcomes) as well as length of hospital stay (secondary outcome).

The primary outcomes of this systematic review were pain scores at 24 hours after the first application of the lidocaine patch and cumulative opioid consumption converted to intravenous morphine equivalent doses\textsuperscript{13} over 24 hours. The secondary outcome was the length of stay in hospital. The visual analog scale (VAS, 0–100 mm) was used as a measure of pain intensity (0 = no pain and 100 = worst pain possible), and scores were analyzed quantitatively. Pain intensity score on the numeric rating scale (NRS, 0–10) was converted to a 0–100 mm VAS score for analysis (VAS = NRS × 10 mm). Opioid analgesics were converted to intravenous morphine equivalent doses (in mg)\textsuperscript{14}. If trials did not report data at our pre-specified study time points, we selected the closest time point for analysis. We contacted authors by e-mail or phone if additional information was needed.

Our meta-analysis was performed with Review Manager (version 5.2, Cochrane collaboration). For continuous data, mean differences (MD) were analyzed by the inverse variance method. If the 95\% CI included zero, the difference between the lidocaine patch and control groups was not considered as statistically significant. When mean with SD values were not given, they were estimated from the median and SE or CI (SEM = SD/V\textsuperscript{N} and SEM = (95\% CI)/1.96), or from the inter-quartile range if the data distribution was not skewed. Heterogeneity between datasets were assessed by I\textsuperscript{2} and tested by a chi-square (\chi^{2}) test. Random effects models were used if \chi^{2} > 25 or \(p < 0.05\) for the \chi^{2} test. A \(p\)-value \textless 0.05 was considered statistically significant.

Materials and methods

A systemic search was performed without language limitations. We searched MEDLINE, PUBMED, CINAHL, Scopus, and the Cochrane Controlled Trials Register for published prospective controlled clinical trials that evaluated the analgesic effect of lidocaine patches for acute or postoperative pain management (1966 – July 2014). We used free text and the MeSH terms lidocaine, Lidoderm, lignocaine, lidocaine patch, postoperative, analgesia, and acute pain. We recruited additional trials from bibliographies of the retrieved trials and previous reviews. We excluded data from abstracts, case reports, letters, and reviews. Only controlled trials of the lidocaine patch for postoperative analgesia and acute pain management in adults, with a no-treatment or a placebo group, were considered. From these, we extracted information on pain intensity, opioid consumption, and length of hospital stay.

Two reviewers independently read the titles and abstracts of the manuscript to determine whether it met the inclusion criteria (kappa = 1.0). We sought to contact the authors on data that were not reported in the manuscript.

Results

A total of 87 trials were identified from the initial search, of which 82 were excluded, as they were not central to the topic of interest. Five controlled trials comparing a lidocaine patch with placebo or no treatment for postoperative analgesia or acute pain treatment/management were included in this meta-analysis. Data were available on 251 patients. There were four randomized controlled trials\textsuperscript{15–18} and one prospective cohort study\textsuperscript{19}. For the prospective cohort study, during the first 6 month period patients received the lidocaine patch, with patients from the subsequent 6 month period serving as controls. The characteristics of the included studies\textsuperscript{15–19} are shown in Table 1. The flow diagram of the search process is shown in Figure 1. Table 2 presents the risk of biases and Jadad scores of included studies.

Opioid consumption

Three of the five studies provided information on opioid consumption\textsuperscript{15–18}. Two studies did not provide specific information on opioid consumption\textsuperscript{18,19}. Combined data
### Table 1. Characteristics of eligible trials.

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>No. of patients</th>
<th>Age (years)</th>
<th>Surgery</th>
<th>Intervention</th>
<th>Control</th>
<th>End points and outcomes</th>
<th>Postoperative analgesics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saber et al., 2009&lt;sup&gt;16&lt;/sup&gt;</td>
<td>15</td>
<td>52.33 ± 17.62</td>
<td>Laparoscopic Ventral Hernia Repair</td>
<td>Lidocaine patch: placed uncut patches over the site of the mesh, 12 hours daily for 3 days</td>
<td>No treatment</td>
<td>Pain score (at discharge), opioid consumption, length of hospital stay</td>
<td>IV morphine 1–4 mg q4h PRN. PO acetaminophen 500 mg and oral hydrocodone 5 mg q4h PRN</td>
</tr>
<tr>
<td>Habib et al., 2009&lt;sup&gt;15&lt;/sup&gt;</td>
<td>36</td>
<td>58 ± 7</td>
<td>Radical Retropubic Prostatectomy</td>
<td>Lidocaine patch: cut into two halves, each on one side of the wound for 24 hours</td>
<td>Placebo patch</td>
<td>Pain score (at 24 h postoperation), opioid consumption, length of hospital stay</td>
<td>PCA morphine PRN; ketorolac 15 mg q6h</td>
</tr>
<tr>
<td>Ingalls et al., 2010&lt;sup&gt;17&lt;/sup&gt;</td>
<td>33</td>
<td>54.8 ± 3.1</td>
<td>Traumatic Rib Fractures</td>
<td>Lidocaine patch: over the site of rib fracture every 12 hours for 72 hours or until discharge</td>
<td>Placebo patch</td>
<td>Pain score (average over first 72 h postoperation), opioid consumption, length of hospital stay</td>
<td>IV morphine 2–4 mg q2h PRN; PO hydrocodone/acetaminophen 5/500 mg tablet, 1–2 tablets q4h PRN</td>
</tr>
<tr>
<td>Khanna et al., 2012&lt;sup&gt;19&lt;/sup&gt;</td>
<td>31</td>
<td>59.3 ± 11.3</td>
<td>Total Knee Arthroplasty</td>
<td>Lidocaine patch: placed uncut patches around the incision, 12 hours daily for 11 days</td>
<td>No treatment</td>
<td>Pain score (on postoperative day 1), length of hospital stay</td>
<td>Acetaminophen, non-steroidal anti-inflammatory drugs, and PCA/IV morphine PRN</td>
</tr>
<tr>
<td>Kwon et al., 2012&lt;sup&gt;18&lt;/sup&gt;</td>
<td>20</td>
<td>43.64 ± 7.94</td>
<td>Gynecologic Laparoscopic Surgery</td>
<td>Lidocaine patch: divided into four small patches, applied at the four laparoscopic port sites, changed every 12 hours for 36 hours</td>
<td>Placebo patch</td>
<td>Pain score (at 6 h postoperation), opioid consumption, length of hospital stay</td>
<td>Rescue: IV ketorolac 15 mg, followed by IV demerol 25 mg</td>
</tr>
</tbody>
</table>

PCA patient-controlled analgesia; IV intravenous; PO per oral; PRN as needed; q2h every 2 hours; q4h every 4 hours; q6h every 6 hours.
from three studies showed no significant difference in opioid consumption between the lidocaine patch group and the control group (MD: −8.2 mg [95% CI: −28.68, 12.24], Z = 0.79, p = 0.43; I² = 88%) (Figure 2).

**Postoperative pain**

All five trials provided information on pain scores at 24 hours15–19. Combined data showed no significant difference in pain intensity at rest between the lidocaine patch group and the control group (MD = −9.1 mm [95% CI: −23.31, −5.20], Z = 1.24, p = 0.21; I² = 99%) (Figure 3).

**Length of hospital stay**

All five studies reported data for the length of hospital stay (no ambulatory/day surgery). Combined data showed no significant difference in hospital stay between the lidocaine patch group and the control group (MD = −0.2 days [95% CI: −0.80, 0.43], Z = 0.60, p = 0.55; I² = 43%) (Figure 4).

**Adverse events**

In all five trials, use of the lidocaine patch was not associated with any adverse effects, such as wound complications, contact dermatitis and systemic side effects.

**Sensitivity analysis**

We repeated all analysis without the prospective cohort study19 and the results were similar.

**Publication biases**

Funnel plots of all three outcome variables are shown in Figures 2–4.
Table 1. Cumulative opioid consumption (morphine equivalent, mg).

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Lidocaine Patch</th>
<th>Control</th>
<th>Mean Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Habib 2009&lt;sup&gt;16&lt;/sup&gt;</td>
<td>45 37 36</td>
<td>43 33 34</td>
<td>2.09 [-14.40, 18.40]</td>
<td></td>
</tr>
<tr>
<td>Ingalls 2010&lt;sup&gt;17&lt;/sup&gt;</td>
<td>63 30 33</td>
<td>96 35 25</td>
<td>-33.00 [-50.12, -15.88]</td>
<td></td>
</tr>
<tr>
<td>Saber 2009&lt;sup&gt;16&lt;/sup&gt;</td>
<td>15.4 3.8 15</td>
<td>12.2 5 15</td>
<td>3.20 [0.02, 6.38]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>84</td>
<td>74</td>
<td>-8.22 [-28.68, 12.24]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau<sup>2</sup> = 280.88; Chi<sup>2</sup> = 16.61, df = 2 (P = 0.0002); I<sup>2</sup> = 88%
Test for overall effect: Z = 0.79 (P = 0.43)

Figure 2. Cumulative opioid consumption (morphine equivalent, mg).

Table 2. Pain scores (visual analog scale or equivalent, mm).

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental</th>
<th>Control</th>
<th>Mean Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Habib 2009&lt;sup&gt;15&lt;/sup&gt;</td>
<td>17 4 36</td>
<td>16 5 34</td>
<td>20.3% 1.00 [-5.12, 7.12]</td>
<td></td>
</tr>
<tr>
<td>Ingalls 2010&lt;sup&gt;17&lt;/sup&gt;</td>
<td>56 4 33</td>
<td>60 3 25</td>
<td>21.0% -4.00 [-8.80, -2.20]</td>
<td></td>
</tr>
<tr>
<td>Khanna 2012&lt;sup&gt;19&lt;/sup&gt;</td>
<td>74 23 31</td>
<td>71 14 22</td>
<td>19.1% 3.00 [-6.99, 12.99]</td>
<td></td>
</tr>
<tr>
<td>Kwon 2012&lt;sup&gt;18&lt;/sup&gt;</td>
<td>20 3 48</td>
<td>20 4 20</td>
<td>21.0% -28.00 [-30.19, -25.81]</td>
<td></td>
</tr>
<tr>
<td>Saber 2009&lt;sup&gt;16&lt;/sup&gt;</td>
<td>31.3 16.8 15</td>
<td>48 14.2 15</td>
<td>18.7% -16.70 [-27.83, -5.57]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>135</td>
<td>116</td>
<td>-9.05 [-23.31, 5.20]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau<sup>2</sup> = 251.12; Chi<sup>2</sup> = 306.13, df = 4 (P < 0.00001); I<sup>2</sup> = 99%
Test for overall effect: Z = 1.24 (P = 0.21)

Figure 3. Pain scores (visual analog scale or equivalent, mm).
Discussion

This meta-analysis showed that application of a lidocaine patch did not significantly reduce postoperative pain scores, opioid consumption, or length of hospital stay. Although the patch is associated with minimal systemic absorption and side effects, it might not be an effective adjunct for the management of acute pain.

We postulated three major reasons for the insignificant results. First, the lidocaine patch delivers lidocaine to the intact skin around the wound instead of directly into the wound (in contrast with wound infiltration). Second, the lidocaine diffuses from the epidermis to the deeper parts of skin instead of spreading under the epidermis or even under the dermis like wound infiltration. Third, the lidocaine patch has minimal systemic absorption. It has fewer systemic side-effects but also less analgesic effect than intravenous lidocaine. Therefore, the lidocaine patch might not reliably reduce postoperative pain and thus did not affect the opioid consumption and length of hospital stay.

The topical lidocaine 5% patch is a 10 cm by 14 cm soft, stretchy adhesive patch that contains 700 mg of 5% lidocaine in an aqueous base. It delivers the drug around the wound or on top of intact skin, with the amount absorbed directly related to the duration of application and skin area covered. Lidocaine exerts both its analgesic and local anesthetic effects by blocking sodium channels. Lidocaine within the patch penetrates the skin and stabilizes the neuronal membranes of pain fibers by binding to receptors within sodium channels. These channels have been found to be present in abnormally high numbers in hyperactive or damaged nociceptors. Bound lidocaine blocks the influx of sodium ions, reducing the abnormal ectopic discharges produced by damaged and dysfunctional peripheral nerves, thus interrupting the conduction of the pain signal. However, by diffusion, the concentration of lidocaine reduces by 94% across the stratum corneum (lidocaine concentration reduced to 0.3% for a 5% lidocaine patch). The lidocaine patch may effectively reduce the pain on the skin just below the patch but theoretically it has almost no analgesic effect on the skin outside the patch. Unless putting the patch over the wound, lidocaine patches may not have effective analgesic effects on the most painful location. Furthermore, the concentration continues to drop by roughly 50% for each 1 mm below the stratum corneum. The depth of analgesic effects of the lidocaine patch is not comparable to wound infiltration of lidocaine.

The lidocaine patch formulation is designed to deliver sufficient lidocaine to block sodium channels in nociceptors and reduce the generation of pain impulses.
but not enough to block sodium channels on large myelinated Aβ fibers. The lidocaine patch therefore produces analgesia at the local site of action without producing local anesthesia, with the skin underneath the patch continuing to have normal sensation. This is known as ‘targeted peripheral analgesia’. It is important to contrast this with transdermal patches (e.g. the fentanyl patch) that incorporate a drug delivery system into the patch and depend on absorption of drug into the systemic circulation to produce analgesia. Pharmacokinetic studies have shown that the systemic absorption of lidocaine from the patch is minimal with a mean maximum plasma concentration of 0.13 μg/mL, which is about 10% of the antiarrhythmic dose, resulting in a low risk of systemic side effects. However, the limited systemic absorption means not only minimal systemic side-effects but also minimal analgesic effects systematically. There are limitations to this meta-analysis. There are a limited number of studies using a lidocaine patch in the acute pain setting and most had a relatively small sample size. The placebo groups in two studies were not completely blinded. Also, the etiologies of pain, method of applying lidocaine patches, surgery and study populations were heterogeneous. Adjunct analgesics were not reported in all included studies. Those analgesics may affect the pain scores or opioid consumption.

Conclusion

This systematic review suggests that the application of a lidocaine patch may not be an effective adjunct for postoperative pain or acute pain management, in terms of postoperative pain scores, opioid consumption and length of hospital stay. Additional large, well designed studies are needed to confirm these findings.

Transparency

Declaration of funding

This study was not funded by any company. The authors are paying for priority services.

Declaration of financial or other relationships

Y.B., T.M., M.T., L.S.-C.L., and T.J.G. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

The authors thank the faculty and other scientists of their department for their valuable comments.

Previous presentation: This paper was presented in the annual meeting of the Department of Anesthesiology, Duke University, Durham, NC, USA.

References


© 2015 Informa UK Ltd www.cmrojournal.com

Lidocaine patch for acute pain management Bai et al.